Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0795 • ACR Convergence 2025
Molecular Stratification of Rheumatoid Arthritis Patients by Multi-Omics Integration Reveals Disease Status and Predictors of Therapeutic Response
Ismael Sanchez-Pareja¹, Daniel Toro², Carlos Pérez Sánchez³, Laura muñoz-Barrera¹, Tomás Cerdó¹, Elena Moreno-Caño⁴, Sagrario Corrales¹, Lydia Formanti Alonso⁵, Rafaela Ortega-Castro⁶, Jerusalén Calvo⁵, Lourdes Ladehesa⁷, Concepción Aranda-Valera⁵, M Carmen Abalos-Aguilera⁸, Christian Merlo-Ruiz⁸, MARIA ANGELES AGUIRRE ZAMORANO¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero Contreras⁵ and Chary López pedrera¹⁰, ¹Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ²GENYO / Karolinska Institutet, Granada / Stockholm, Spain, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/ CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ⁴IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Córdoba, Spain, ⁵IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁶Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁷IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain
Background/Purpose: To characterize molecular profiles of RA patients through multi-omics integration and evaluate their associations with disease status and therapeutic response to csDMARDs, TNF inhibitors…
Abstract Number: 0492 • ACR Convergence 2025
Outcomes of Total Knee Replacement in Patients with Rheumatoid Arthritis: A National Inpatient Sample Database Analysis
karun Shrestha¹, Pravakar Parajuli², Anil Regmi³, Prakriti Subedi⁴, Manoj Ghimire⁵, Sajana Poudel⁶, Mohammed Hasan⁷, Mahmoud Hashim⁸, Veera Durga Vaishnavi Kurra⁹ and ClementT Taoge¹⁰, ¹Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY ¹⁰⁴⁵⁷, USA, BRONX, NY, ²Patan Academy of Health Sciences-School of Medicine (PAHS-SOM), Lalitpur, Bagmati, Nepal, ³Parkview Health, Fort Wayne, IN, ⁴St. Barnabas Hospital, Bronx, NY, ⁵St Barnabas Hospital, BRONX, NY, ⁶Cook County Health, CHICAGO, NY, ⁷Parkview Medical Center, Pueblo, CO, ⁸SBH Health System, New Rochelle, NY, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Albert Einstein College of Medicine - Montefiore Medical Center, Bronx
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease of the joints with an estimated prevalence of 0.5% of people. Nearly 25% of RA patients…
Abstract Number: 0476 • ACR Convergence 2025
Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence
Maxim Korolev¹, Alexander Dubikov², Daria Bukhanova³, Alina Egorova³, Eugenyi Alekseev⁴, Sofia Kuzkina⁵ and Mikhail Samsonov³, ¹Research Institute of Clinical and Experimental Lymрhology – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia, ²Rheumatology clinic of Professor Dubikov A.I., Vladivostok, Russia, ³R-Pharm JSC, Moscow, Russia, ⁴"R-Pharm", JSC, Moscow, Russia, ⁵R-Pharm, Moscow, Russia
Background/Purpose: Comorbidities may affect the efficacy of bDMARDs in rheumatoid arthritis (RA). Post-hoc analysis of the randomized clinical trial (RCT) data shows that the efficacy…
Abstract Number: 0460 • ACR Convergence 2025
The Impact of Early and Artificial Menopause on Dementia Risk Among Women with Rheumatoid Arthritis
Ryan Salama¹, Cassondra Hulshizer², Cynthia Crowson³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Alzheimer’s disease and related dementias present an increasing global health concern, with increasing incidence and prevalence. Hormonal fluctuations associated with menopause may exacerbate inflammatory…
Abstract Number: 0443 • ACR Convergence 2025
Association between pan-immune-inflammation and synovitis as assessed by ultrasound in rheumatoid arthritis
Elvira E Aguilar-Oliva¹, Luis M Amezcua-Guerra², ismael valenzuela³, Carina Soto-Fajardo⁴, Karina Arias⁵, Alejandra Espinosa⁶, Carlos Pineda⁴ and Luis H Silveira⁷, ¹Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, TLALPAN, Distrito Federal, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico city, ³Instituto Nacional de Cardiología Ignacio Chávez, TLALPAN, Distrito Federal, Mexico, ⁴National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Mexico City, Mexico, ⁵Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Tlalpan, Distrito Federal, Mexico, ⁶National Rehabilitation Institute " Luis Guillermo Ibarra Ibarra ", Ciudad de México, Mexico, ⁷Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico
Background/Purpose: The pan-immune-inflammation value (PIV) is a novel composite biomarker derived from blood count parameters, reflecting the systemic balance of immune-inflammatory activity. Although it has…
Abstract Number: 0370 • ACR Convergence 2025
Patient Preferences for Treatments of Rheumatoid Arthritis: A Discrete Choice Experiment Evaluating Preference for Advanced Drug Therapies and Neuroimmune Modulation Device
Jeffrey Curtis¹, Joshua Baker², Shilpa Venkatachalam³, Sherry Danese⁴, Julie Ulloa⁵ and Ankit Shah⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Global Healthy Living Foundation, New York, NY, ⁴OutcomesInsights, Calabasas, CA, ⁵OutcomesInsights, Calabasas, ⁶SetPoint Medical, Valencia, CA
Background/Purpose: Despite broadening treatment options for RA, several challenges and unmet needs remain. The 2021 ACR guideline for the treatment of RA marked a significant…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 0146 • ACR Convergence 2025
Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
Bhavik Bansal¹, Yehseo Jung², Abdulla Damluji³, Parag Goyal⁴ and Namrata Singh⁵, ¹UT Southwestern Medical Centre, Dallas, TX, ²University of Washington, Seattle, WA, ³Johns Hopkins, Baltimore, ⁴Weill Cornell, New York, ⁵University of Washington, Bellevue, WA
Background/Purpose: We investigated the association of frailty and delirium, both independently and in combination, with in-hospital mortality and non-routine discharge (i.e. when a patient is…
Abstract Number: 0078 • ACR Convergence 2025
Citrullinated Serum Albumin Is Not an Autoantigen in Rheumatoid Arthritis
Farheen Sultan Shaikh, cecilia mustelin, Xiaoxing Wang and Tomas Mustelin, University of Washington, Seattle, WA
Background/Purpose: Autoantibodies against citrullinated proteins (ACPAs) are diagnostic of rheumatoid arthritis (RA), an autoimmune disease primarily affecting synovial joints. Proteomic analyses have identified human serum…
Abstract Number: 0060 • ACR Convergence 2025
Dietary Management of Rheumatoid Arthritis: A Functional Investigation of the Synbiotic Medical Food, SBD121
Ryan Green¹, Daniela Diaz-Infante Morales¹, Alicia Ballok¹, Kristine Kuhn², Christopher Ritchlin³, Mark Charbonneau¹, Eric Schott¹ and Gerardo Toledo¹, ¹Solarea Bio Inc, Waltham, MA, ²²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO, ³University of Rochester Medical Center, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA), affecting approximately 1% of the global population RA is a leading cause of disability worldwide. Despite available treatments, including methotrexate (MTX)…
Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Stevie Barry¹, Katie McMenamin², Austin Wheeler³, Bryant England³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Rui Xiao¹, Sylvanus Toikumo¹⁴, Henry Kranzler¹⁴, Rachel Kember¹⁴, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls³, Joshua Baker¹ and Thomas Riley¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston Medical Center, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
Abstract Number: 2614 • ACR Convergence 2025
Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis
Charles Peterfy, MD, PhD¹, John Tesser², Yaakov Levine³, Melissa Evangelista⁴, Vibeke Strand⁵, Michael Weinblatt⁶ and David Chernoff⁷, ¹Spire Sciences, Inc., Boca Raton, FL, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³SetPoint Medical, Valencia, CA, ⁴SetPoint Medical Corporation, Valencia, CA, ⁵Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷SetPoint Medical, Sausalito, CA
Background/Purpose: Previously reported results from RESET-RA (ClinicalTrials.gov, NCT04539964) showed neuroimmune modulation via electrical stimulation of the left vagus nerve using an implantable device to treat…
Abstract Number: 2284 • ACR Convergence 2025
Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Sila Mateo Faxas¹, Godbless Ajenaghughrure¹, Gurjot Singh², Kim Nguyen², Nirys Mateo Faxas³, Nicole Tejeda⁴, Kimberly Ramirez Bonetti⁵ and Erick Perez Mejias⁴, ¹Trihealth Good Samaritan Hospital, Cincinnati, OH, ²Trihealth Good Samaritan Hospital, Cincinnati, ³Independent Author, Santo Domingo, Dominican Republic, ⁴Independent Author, Cincinnati, ⁵Independent Author, cincinnati, OH
Background/Purpose: Patients with rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM) face increased cardiovascular risk. Different biologic disease-modifying antirheumatic drugs (bDMARDs) may have varying…
Abstract Number: 2268 • ACR Convergence 2025
Differential Impact of Certolizumab Pegol, Etanercept, and Adalimumab on Rheumatoid Factor Reduction and Seroconversion in Rheumatoid Arthritis: A Propensity Score–Matched Study
Clementina López Medina¹, Rafaela Ortega-Castro², Francisco Jose Cepas³, Montserrat Robustillo-Villarino⁴, Andres Zuniga-Vera⁴, Ana Martinez-Feito⁵, Ester Costa-Moya⁶, Delia Taverner-Torrent⁶, Luis Sainz Comas⁷, Cesar Diaz-Torne⁷, Virginia Ruiz-Esquide⁸, Cynthia Rojas⁹, Lourdes Martin-de la Sierra Lopez¹⁰, Laura Jimenez-Rodriguez¹⁰, David Velasco-Sanchez¹⁰, Regina Fará Garcia¹¹, Antonio Juan-Mas¹², Marina soledad Moreno Garcia¹³, Ana Valeria Acosta Alfaro¹⁴, Santiago Muñoz¹⁵, Maria Martín López¹⁶, Raquel Zas¹⁷, FRANCISCO JAVIER GODOY NAVARRETE¹⁸, Isabel Anon Onate¹⁹, Fernando Ortiz-Márquez²⁰, Natalia Mena Vázquez²¹, Paula Estrada-Alarcón²², Jerusalén Calvo²³, Alejandro Escudero Contreras²³ and Chamaida Plasencia-Rodríguez²⁴, ¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³University of Cordoba, Cordoba, Spain, ⁴Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁵Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁶Hospital Sant Joan Reus, Reus, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹Hospital Clinic, Barcelona, Spain, ¹⁰Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹¹Hospital Son Llàtzer, Palma, Spain, ¹²Son Llazter University Hospital, Madrid, Spain, ¹³Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁴Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁵Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁶Hospital ¹² de Octubre, Madrid, Spain, ¹⁷Hospital Universitario Doce de Octubre, Madrid, Spain, ¹⁸Jaen University Hospital, Spain, Jaen, Spain, ¹⁹Hospital Universitario de Jaén, Jaén, Spain, ²⁰Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²¹Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ²⁴Hospital Universitario La Paz, MADRID, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody that contributes to the development of rheumatoid arthritis (RA) and is associated with greater disease severity. Seroconversion of…
Abstract Number: 2252 • ACR Convergence 2025
Association between frailty and survival among older adults with rheumatoid arthritis and lung cancer
Michelle Nguyen¹, Aaron Baraff², Alexander Peterson², Alexandra Schmidt², Katherine Wysham³, Aliyah Pabani⁴, Carolyn Presley⁵, Nicholas Smith¹, Shelly Gray¹, Jose Garcia⁶, Ariela Orkaby⁷ and Namrata Singh¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Johns Hopkins, Washington, DC, ⁵Ohio State University Medical Center, Columbus, ⁶VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁷VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA
Background/Purpose: Individuals with rheumatoid arthritis (RA) have a higher prevalence of frailty, even at younger ages, compared to the general population1. Among persons with lung…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].